United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Apple

Intel

Microsoft

Exxon Mobil

It takes a certain kind of courage to short sell blue chips, such as the Dow Jones industrial average components.

The 5 Most Shorted Dow Stocks (April 13)

AbbVie

Bristol-Myers

The time is right and the price is right to buy these big pharma stocks.

3 Top Pharma Stocks to Buy in April

Dr. Mikael Dolsten of Pfizer Inc. (NYSE:PFE) stated on Thursday that the American multinational pharmaceutical corporation has identified a drug candidate as a potential treatment for Coronavirus.

Pfizer identifies an antiviral drug as a potential treatment of Coronavirus

Pfizer's Braftovi Approval, And Other News: The Good, Bad And Ugly Of Biopharma

BioNTech SE

Drugmaker Pfizer said Thursday that it is working on a promising treatment for coronavirus, as well as vaccine. The drugmaker said preclinical studies showed that an unspecified compound that was originally used to treat SARS — a different coronavirus — has shown potential in battling the dangerous illness.

Pfizer working on promising coronavirus treatment, vaccine

The therapeutic, "if successful, would be given early in the disease process, when patients are admitted to the hospital," Pfizer Chief Scientific Officer Dr. Mikael Dolsten said Thursday.

Pfizer's lead coronavirus drug is showing promise, chief scientific officer says

The enormity of the coronavirus pandemic has forced biopharma companies to step up efforts to expeditiously develop vaccines and treatments for COVID-19.

Pfizer, BioNTech, Arcturus Share Timelines For Human Testing As COVID-19 Vaccine Development Intensifies

Eli Lilly

Pfizer (PFE) secures an FDA approval for Braftovi combined with Lilly's Erbitux to treat BRAFV600E-mutant metastatic colorectal cancer in patients who received prior therapy.

Pfizer's Braftovi Combo Gets FDA Nod for Colorectal Cancer

Gilead Sciences

Pfizer stock jumped Thursday after the pharma giant identified a potential coronavirus treatment and inked a deal with BioNTech for a vaccine. Gilead updated its remdesivir studies.

Covid Report: Pfizer Selects Lead Coronavirus Drug; Gilead Updates Tests

The two drugmakers also revealed financial details of their SARS-CoV-2 vaccine collaboration.

Pfizer and BioNTech Aim to Start Testing Coronavirus Vaccines in Humans by Late April

Pfizer Inc. (NYSE: PFE) and BioNTech S.E.

Will the Pfizer-BioNTech Collaboration Be a Winner in the Fight Against COVID-19?

Shares of Pfizer Inc. PFE, +2.94% were up 0.6% in premarket trading on Thursday after the drugmaker disclosed it is paying BioNTech BNTX, -1.42% $185 million for their COVID-19 vaccine development collaboration, with additional possible future milestone payments up to $563 million.

Pfizer discloses $185 million upfront payment to BioNTech for COVID-19 vaccine program

MAINZ, Germany, and NEW YORK, April  09, 2020  (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), and Pfizer Inc. (NYSE: PFE) today disclosed additional details of their collaboration to advance candidates from BioNTech’s mRNA vaccine program, previously announced on March 17, 2020.

Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development

AstraZeneca

GlaxoSmithKline

Moderna

Sanofi

Telesis Bio Inc

Biotech and big pharma are putting vaccines using messenger RNA to the coronavirus test.

Is mRNA the Key to a Coronavirus Vaccine?

Johnson & Johnson

Merck

Novartis

Large-Cap Pharma Stocks to Benefit in Post-Pandemic Market

Arista Networks

Cisco Systems

Dell Technologies

Walgreens

Wells Fargo

Not all blue-chip stocks are good to hold forever. These companies are struggling to cut costs and could fall further.

7 Tarnished Blue-Chip Stocks to Ditch Now

Amazon

Monday's big stock charts feature names that may have downside protection in the form of trend-line support.
The post 3 Big Stock Charts for Monday: Intel, Amazon, and Pfizer appeared first on InvestorPlace.

3 Big Stock Charts for Monday: Intel, Amazon, and Pfizer

The pharma giants want to help any way they can, and that means letting their thousands of medical professionals go where they are most urgently needed.

Pfizer, Merck, and Eli Lilly Will Pay Their Doctors to Get Back to Treating Patients During the COVID-19 Pandemic

While the outlook for both companies remains strong, as both the companies have a strong pipeline and existing drugs portfolio to drive revenue growth, we believe Merck could be a better bet in the current environment.

Sell Pfizer To Buy Merck?

Aerie Pharmaceuticals

Axsome Therapeutics

Biogen

bluebird bio

Puma Biotechnology

Rigel Pharmaceuticals

Success in clinical trials doesn't guarantee success on the market.

So Your Biotech Announced Positive Phase 3 Results? Celebrating Could be Premature

Pfizer (PFE) closed at $32.66 in the latest trading session, marking a -0.03% move from the prior day.

Pfizer (PFE) Stock Moves -0.03%: What You Should Know

Pfizer has been a big loser recently. But it could be on a course to return to its winning ways of the past.

Is Pfizer a Great Stock to Buy During the Coronavirus Market Crash?

Amgen

iShares Nasdaq Biotechnology ETF

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

Drug developers took center stage as the world looks to these companies to deliver an answer to COVID-19.

4 Reasons Drug Stocks Are a Buy Right Now

News for Pfizer Stock (PFE)